Welcome to our dedicated page for Medexus Pharmace news (Ticker: MEDXF), a resource for investors and traders seeking the latest updates and insights on Medexus Pharmace stock.
Medexus Pharmaceuticals Inc. reports news on its specialty pharmaceutical portfolio and North American commercial operations. The company's updates center on GRAFAPEX (treosulfan) for Injection in the United States, financial results, and product-level trends across therapeutic areas that include hematology and hematology-oncology, rheumatology, allergy, and dermatology.
Medexus news also covers capital allocation and capital structure actions, including credit facilities, warrant expirations, and normal course issuer bid activity, along with shareholder meeting results, conference calls, and management participation in investor conferences.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) will participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference scheduled for April 25-26, 2023, in Toronto, Ontario.
The company’s presentation, featuring Ken d’Entremont, CEO, and Marcel Konrad, CFO, will take place on April 25 at 9:30 AM ET. Attendees can engage in in-person one-on-one meetings during the event.
A live and recorded webcast of the presentation will be available on the Investors—News & Events section of Medexus’s corporate website. The focus of Medexus is on innovative treatments in hematology, auto-immune diseases, and allergy.
Medexus Pharmaceuticals announced preliminary revenue estimates for the fiscal year 2023, expecting to exceed US$107 million, an all-time record, with fiscal Q4 2023 revenue projected at US$28 million to US$28.5 million, marking a year-over-year increase of at least 38.1%.
This growth is driven by strong sales in several products: IXINITY saw positive trends in new patient conversions; Rasuvo maintained its leading position in the US branded methotrexate market; Rupall demonstrated sustained demand growth; and Gleolan achieved its best month in fiscal year 2023.
Additionally, the company announced a board update, appointing Mike Mueller as chair after Peter van der Velden's departure, reflecting a stable leadership transition as Medexus continues to progress.
Medexus Pharmaceuticals (OTCQX: MEDXF) has gained Canadian rights to commercialize terbinafine hydrochloride nail lacquer, supplied by Polichem. This product, used for treating fungal nail infections, will be submitted for Health Canada approval later this year. The Canadian fungicides market is estimated at C$88 million annually. CEO Ken d’Entremont indicated that the product would bolster revenues and leverage their existing commercial platform, complementing their leading product, Rupall®. Medexus will pay Polichem a low double-digit royalty on net sales and has structured the deal to minimize initial costs.